FDA Approves First In Class Targeted Therapy For Metastatic Pancreatic Cancer
RVMD•FDA approves first-in-class targeted therapy
- FDA approves first-in-class targeted therapy for metastatic pancreatic cancer
- U.S. FDA approves Rasonque (daraxonrasib), first-in-class RAS inhibitor for metastatic pancreatic cancer
Further company coverage: RVMD.O
